Predicting potent drug combinations by exploiting monotherapy resistance

Información del proyecto

COMBAT-RES

Identificador del acuerdo de subvención: 950293

DOI

10.3030/950293

Proyecto finalizado el 1 Octubre 2025

Fecha de la firma de la CE 17 Noviembre 2020

Fecha de inicio 1 Enero 2021

Fecha de finalización 31 Diciembre 2025

Financiado con arreglo a

• EXCELLENT SCIENCE - European Research Council (ERC)

Coste total

€ 1 499 991,00

Aportación de la UE

€ 1 499 991,00

Coordinado por

HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
Germany

CORDIS proporciona enlaces a los documentos públicos y las publicaciones de los proyectos de los programas marco HORIZONTE.

Los enlaces a los documentos y las publicaciones de los proyectos del Séptimo Programa Marco, así como los enlaces a algunos tipos de resultados específicos, como conjuntos de datos y «software», se obtienen dinámicamente de OpenAIRE .

Publicaciones

Peer reviewed articles (16)

Generative artificial intelligence empowers digital twins in drug discovery and clinical trials

Autores: M Bordukova, N Makarov, R Rodriguez-Esteban, F Schmich, MP Menden
Publicado en: Expert Opinion on Drug Discovery, 2024, Página(s) 19 (1), 33-42, ISSN 1746-0441
Editor: Informa Healthcare
DOI: 10.1080/17460441.2023.2273839

Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer

Autores: Irineos Papakyriacou, Ginte Kutkaite, Marta Rúbies Bedós, Divya Nagarajan, Liam P. Alford, Michael P. Menden, Yumeng Mao
Publicado en: Nature Communications, Edición 15, 2024, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-024-47987-x

Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma

Autores: Divya Nagarajan, Rebeca T. Parracho, David Corujo, Minglu Xie, Ginte Kutkaite, Thale K. Olsen, Marta Rubies Bedos, Maede Salehi, Ninib Baryawno, Michael P. Menden, Xingqi Chen, Marcus Buschbeck, Yumen
Publicado en: Journal of Clinical Investigation, Edición 134, 2024, ISSN 1558-8238
Editor: American Society for Clinical Investigation
DOI: 10.1172/jci175310

The impact of the cardiovascular component and somatic mutations on ageing

Autores: Daniel Garger, Martin Meinel, Tamina Dietl, Christina Hillig, Natalie Garzorz-Stark, Kilian Eyerich, Martin Hrabě de Angelis, Stefanie Eyerich, Michael P. Menden
Publicado en: Aging Cell, 2023, ISSN 1474-9718
Editor: Blackwell Publishing Inc.
DOI: 10.1111/acel.13957

Can artificial intelligence accelerate preclinical drug discovery and precision medicine?

Autores: Ali Farnoud, Alexander J Ohnmacht, Martin Meinel, Michael P Menden
Publicado en: Expert Opinion on Drug Discovery, 2022, ISSN 1746-0441
Editor: Informa Healthcare
DOI: 10.1080/17460441.2022.2090540

LUBAC modulates CBM complex functions downstream of TRAF6 in T cells

Autores: Carina Graß, Franziska Ober, Constanze Sixt, Bahareh Nemati Moud, Irina Antoshkina, Frederick Eberstadt, Alisa Puhach, Göksu Avar, Antonia Keßler, Thomas J. O’Neill, Thomas Seeholzer, Jan Kranich
Publicado en: Nature Communications, Edición 16, 2025, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-025-65879-6

Oncogene-induced MALT1 protease activity drives post-transcriptional gene expression in malignant lymphomas

Autores: Nicole Wimberger, Franziska Ober, Göksu Avar, Michael Grau, Wendan Xu, Georg Lenz, Michael P. Menden, Daniel Krappmann
Publicado en: Blood, 2023, ISSN 0006-4971
Editor: American Society of Hematology
DOI: 10.1182/blood.2023021299

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Autores: Ohnmacht AJ, Stahler A, Stintzing S, Modest DP, Holch JW, Westphalen CB, Hölzel L, Schübel MK, Galhoz A, Farnoud A, Ud-Dean M, Vehling-Kaiser U, Decker T, Moehler M, Heinig M, Heinemann V, Menden MP
Publicado en: Nature Communications, 2023, ISSN 2041-1723
Editor: Nature Publishing Group
DOI: 10.1038/s41467-023-41011-4

Generative AI and digital twins: shaping a paradigm shift from precision to truly personalized medicine

Autores: Maria Bordukova, Alina J. Arneth, Nikita Makarov, Robyn M. Brown, Elena K. Schneider-Futschik, Shyamali C. Dharmage, Elif Ekinci, Peter J. Crack, Danny M. Hatters, Alastair G. Stewart, David Stroud, T
Publicado en: Expert Opinion on Drug Discovery, Edición 20, 2025, Página(s) 821-826, ISSN 1746-0441
Editor: Informa Healthcare
DOI: 10.1080/17460441.2025.2507376

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity

Autores: Alexander Joschua Ohnmacht, Anantharamanan Rajamani, Göksu Avar, Ginte Kutkaite, Emanuel Gonçalves, Dieter Saur, Michael Patrick Menden
Publicado en: Communications Biology, 2023, ISSN 2399-3642
Editor: Nature
DOI: 10.1038/s42003-023-05198-y

WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice

Autores: Maryam Ghalandary, Yuqiao Gao, Diana Amend, Ginte Kutkaite, Binje Vick, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler, Anetta Marcinek, Marion Subklewe, Michael P. Menden, Vindi Jurinovic, Ehsan Bahrami, Irmela Jeremias
Publicado en: Blood, 2023, Página(s) 141 (8): 955–960., ISSN 0006-4971
Editor: American Society of Hematology
DOI: 10.1182/blood.2022016411

FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters

Autores: Julian Walter Holch, Alexander J. Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Lena Weiss, Victoria Probst, Arndt Stahler, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Florian K
Publicado en: European Journal of Cancer, Edición 220, 2025, Página(s) 115388, ISSN 0959-8049
Editor: Pergamon Press Ltd.
DOI: 10.1016/j.ejca.2025.115388

Artificial intelligence in early drug discovery enabling precision medicine

Autores: Fabio Boniolo, Emilio Dorigatti, Alexander J Ohnmacht, Dieter Saur, Benjamin Schubert, Michael P Menden
Publicado en: Expert Opinion on Drug Discovery, 2021, ISSN 1746-0441
Editor: Informa Healthcare
DOI: 10.1080/17460441.2021.1918096

A statistical framework for assessing pharmacological response and biomarkers using uncertainty estimates

Autores: Dennis Wang; James Hensman; Ginte Kutkaite; Tzen S Toh; Ana Galhoz; GDSC Screening Team; Jonathan R Dry; Julio Saez-Rodriguez; Mathew J Garnett; Michael P Menden; Frank Dondelinger
Publicado en: eLife, 2020, ISSN 2050-084X
Editor: eLife Sciences Publications
DOI: 10.1101/2020.05.01.072983

Large language models forecast patient health trajectories enabling digital twins

Autores: Nikita Makarov, Maria Bordukova, Papichaya Quengdaeng, Daniel Garger, Raul Rodriguez-Esteban, Fabian Schmich, Michael P. Menden
Publicado en: npj Digital Medicine, Edición 8, 2025, ISSN 2398-6352
Editor: Springer Science and Business Media LLC
DOI: 10.1038/s41746-025-02004-3

Inferred Ancestral Origin of Cancer Cell Lines Associates with Differential Drug Response

Autores: Phong Nguyen; Alexander J Ohnmacht; Samir Sharifli; Mathew J. Garnett; Michael P. Menden
Publicado en: International Journal of Molecular Sciences, 2021, ISSN 1422-0067
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/ijms221810135

Conference proceedings (2)

Refining first-line treatment decision in RAS wildtype (RAS-WT) metastatic colorectal cancer (mCRC) by combining clinical biomarkers: Results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).

Autores: Julian Walter Holch, Alexander Ohnmacht, Sebastian Stintzing, Kathrin Heinrich, Benedikt Westphalen, Lena Weiss, Ludwig von Weikersthal, Thomas Decker, Alexander Kiani, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Heinz-Gert Hoeffkes, Markus H Moehler, Dominik Paul Modest, Michael Menden, Volker Heinemann
Publicado en: Journal of Clinical Oncology, 2024, Página(s) 13-13
Editor: American Society of Clinical Oncology
DOI: 10.1200/jco.2024.42.3_suppl.13

DNA METHYLATION PROFILING REFINES THE PROGNOSTIC CLASSIFICATION OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY

Autores: Vosberg, S.; Ohnmacht, A.; Moser, C.; Arneth, A.; Jurinovic, V.; Metzeler, K. H.; Sauerland, M. C.; Görlich, D.; Berdel, W. E.; Braess, J.; Amler, S.; Krug, U.; Hiddemann, W.; Spiekermann, K.; Oakes, C. C.; Menden, M. P.; Herold, T.; Greif, P. A.
Publicado en: HemaSphere, 2022, ISSN 2572-9241
Editor: Wiley
DOI: 10.1097/01.hs9.0000844804.00811.c6